Total Payments
$38,676
2024 Payments
$4,970
Companies
52
Transactions
1,275
Medicare Patients
972
Medicare Billing
$297,824
Payment Breakdown by Category
Food & Beverage$38,419 (99.3%)
Education$257.12 (0.7%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $38,419 | 1,267 | 99.3% |
| Education | $257.12 | 8 | 0.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $10,080 | 278 | $0 (2024) |
| Amgen Inc. | $5,478 | 158 | $0 (2024) |
| UCB, Inc. | $2,356 | 78 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $2,071 | 93 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $1,775 | 52 | $0 (2024) |
| GENZYME CORPORATION | $1,705 | 37 | $0 (2024) |
| PFIZER INC. | $1,694 | 87 | $0 (2024) |
| Lilly USA, LLC | $1,687 | 69 | $0 (2024) |
| Mallinckrodt Hospital Products Inc. | $1,611 | 48 | $0 (2024) |
| Janssen Biotech, Inc. | $1,456 | 70 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $4,970 | 143 | ABBVIE INC. ($1,342) |
| 2023 | $5,827 | 175 | ABBVIE INC. ($1,832) |
| 2022 | $5,190 | 163 | ABBVIE INC. ($1,036) |
| 2021 | $3,797 | 135 | AbbVie Inc. ($1,121) |
| 2020 | $3,169 | 126 | AbbVie Inc. ($787.14) |
| 2019 | $5,235 | 176 | AbbVie, Inc. ($1,619) |
| 2018 | $5,307 | 172 | AbbVie, Inc. ($1,366) |
| 2017 | $5,181 | 185 | AbbVie, Inc. ($977.70) |
All Payment Transactions
1,275 individual payment records from CMS Open Payments — Page 1 of 51
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Lilly USA, LLC | TALTZ (Drug) | Food and Beverage | In-kind items and services | $25.79 | General |
| Category: Immunology | ||||||
| 12/19/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $19.55 | General |
| Category: IMMUNOLOGY | ||||||
| 12/17/2024 | AstraZeneca Pharmaceuticals LP | SAPHNELO (Biological) | Food and Beverage | In-kind items and services | $19.79 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 12/16/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $29.88 | General |
| Category: Immunology | ||||||
| 12/13/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $26.56 | General |
| 12/12/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $93.74 | General |
| Category: Immunology | ||||||
| 12/12/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $31.25 | General |
| Category: Immunology | ||||||
| 12/12/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $12.64 | General |
| Category: IMMUNOLOGY | ||||||
| 12/10/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $26.19 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 12/10/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $1.43 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 12/04/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $22.45 | General |
| Category: IMMUNOLOGY | ||||||
| 11/25/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $8.00 | General |
| Category: IMMUNOLOGY | ||||||
| 11/20/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $26.14 | General |
| Category: IMMUNOLOGY | ||||||
| 11/19/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $33.54 | General |
| Category: Immunology | ||||||
| 11/18/2024 | Amgen Inc. | Enbrel (Biological), Otezla | Food and Beverage | In-kind items and services | $24.99 | General |
| Category: Inflammation | ||||||
| 11/12/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $18.52 | General |
| Category: IMMUNOLOGY | ||||||
| 11/11/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $12.18 | General |
| Category: IMMUNOLOGY | ||||||
| 11/04/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $36.60 | General |
| Category: Immunology | ||||||
| 10/30/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $24.43 | General |
| Category: IMMUNOLOGY | ||||||
| 10/28/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $23.07 | General |
| Category: Inflammation | ||||||
| 10/25/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $15.92 | General |
| Category: IMMUNOLOGY | ||||||
| 10/24/2024 | AstraZeneca Pharmaceuticals LP | SAPHNELO (Biological) | Food and Beverage | In-kind items and services | $21.29 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 10/21/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $47.04 | General |
| Category: Immunology | ||||||
| 10/17/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $27.25 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 10/16/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $19.97 | General |
| Category: IMMUNOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 214 | 2,303 | $302,407 | $81,518 |
| 2022 | 7 | 240 | 1,983 | $266,130 | $75,537 |
| 2021 | 7 | 256 | 1,842 | $275,839 | $81,404 |
| 2020 | 8 | 262 | 805 | $213,546 | $59,366 |
Total Patients
972
Total Services
6,933
Medicare Billing
$297,824
Procedure Codes
28
All Medicare Procedures & Services
28 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 16 | 1,680 | $117,600 | $30,948 | 26.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 96 | 281 | $73,378 | $25,030 | 34.1% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 21 | 105 | $49,560 | $10,533 | 21.3% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 22 | 163 | $42,706 | $9,420 | 22.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 32 | 47 | $8,300 | $2,816 | 33.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 27 | 27 | $10,863 | $2,770 | 25.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 100 | 311 | $81,211 | $29,142 | 35.9% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 13 | 1,320 | $84,480 | $22,424 | 26.5% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 17 | 99 | $49,401 | $11,030 | 22.3% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2022 | 20 | 90 | $25,020 | $5,535 | 22.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 44 | 61 | $10,773 | $3,531 | 32.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 29 | 29 | $11,668 | $3,030 | 26.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 17 | 73 | $3,577 | $846.54 | 23.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 107 | 318 | $83,039 | $29,554 | 35.6% |
| J0897 | Injection, denosumab, 1 mg | Office | 2021 | 11 | 1,140 | $68,400 | $18,700 | 27.3% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2021 | 20 | 118 | $56,168 | $14,025 | 25.0% |
| 96401 | Non-hormonal anti-neoplastic chemotherapy beneath the skin or into muscle | Office | 2021 | 20 | 156 | $41,652 | $10,418 | 25.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 54 | 66 | $11,656 | $4,154 | 35.6% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 24 | 24 | $9,656 | $3,007 | 31.1% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 20 | 20 | $5,268 | $1,545 | 29.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 105 | 324 | $84,606 | $24,580 | 29.1% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2020 | 19 | 111 | $47,730 | $12,436 | 26.1% |
| 96401 | Non-hormonal anti-neoplastic chemotherapy beneath the skin or into muscle | Office | 2020 | 17 | 178 | $43,610 | $11,383 | 26.1% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 29 | 29 | $11,668 | $3,412 | 29.2% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 44 | 60 | $10,596 | $3,412 | 32.2% |
About Dr. Carlos Ramirez, M.D
Dr. Carlos Ramirez, M.D is a Rheumatology healthcare provider based in Pearland, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/13/2006. The National Provider Identifier (NPI) number assigned to this provider is 1982629309.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Carlos Ramirez, M.D has received a total of $38,676 in payments from pharmaceutical and medical device companies, with $4,970 received in 2024. These payments were reported across 1,275 transactions from 52 companies. The most common payment nature is "Food and Beverage" ($38,419).
As a Medicare-enrolled provider, Ramirez has provided services to 972 Medicare beneficiaries, totaling 6,933 services with total Medicare billing of $297,824. Data is available for 4 years (2020–2023), covering 28 distinct procedure/service records.
Ad
Practice Information
- Specialty Rheumatology
- Location Pearland, TX
- Active Since 07/13/2006
- Last Updated 05/10/2022
- Taxonomy Code 207RR0500X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1982629309
Products in Payments
- RINVOQ (Biological) $3,604
- Enbrel (Biological) $3,344
- Humira (Biological) $2,653
- ACTHAR (Biological) $2,533
- Cimzia (Drug) $2,091
- ORENCIA (Biological) $1,977
- SAPHNELO (Biological) $1,726
- SKYRIZI (Biological) $1,459
- TALTZ (Drug) $1,281
- Otezla (Drug) $1,269
- BENLYSTA (Biological) $1,253
- XELJANZ (Drug) $1,131
- KEVZARA (Drug) $1,047
- COSENTYX (Biological) $1,010
- TREMFYA (Drug) $998.14
- KRYSTEXXA (Biological) $769.73
- RINVOQ (Drug) $580.18
- EVENITY (Biological) $552.19
- HUMIRA (Biological) $474.68
- LUPKYNIS (Drug) $473.58
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.